



Cite this: *Mater. Adv.*, 2022,  
3, 7726

Received 1st June 2022,  
Accepted 25th August 2022

DOI: 10.1039/d2ma00625a

rsc.li/materials-advances

## The structural characteristics and mechanisms of antimicrobial carbon dots: a mini review

Baoyan Guo,<sup>†a</sup> Guo Liu,<sup>†b</sup> Chaofan Hu,<sup>ib</sup> Bingfu Lei<sup>ib</sup> and Yingliang Liu<sup>ib\*</sup>

Overuse of antibiotics in agricultural production and medical practices has led to the rapid development of drug-resistant bacteria worldwide, and the emergence of superbacteria has increased the mortality rate of diseases and seriously threatened human life and health. The development of new antibiotics is slow, and resistant bacteria will soon emerge. The substitution of antibiotics with other antimicrobials is, therefore, strongly encouraged. Vaccine development for emerging viruses is slow and has low efficacy. As a new member of the nanomaterial family, carbon dots (CDs) have the advantages of photoluminescence, easy surface functionalization modification, simple preparation, low toxicity, low side effects, and lower probability to develop resistance, showing great antibacterial and antiviral potential. This review summarizes the structural characteristics of CDs with antimicrobial properties and the mechanism of CDs against different types of microorganisms, expecting to provide valuable information for the purposeful synthesis of antimicrobial CDs effective against specific microorganisms in the future.

### 1. Introduction

Antibacterial agents and pesticides are widely used in medicine, food packaging, agriculture, and other aspects, but the side effects of antibacterial agent residues on the body and

environmental pollution are still a problem that cannot be ignored.<sup>1</sup> Overuse of antibiotics and pesticides has led to resistance of microorganisms.<sup>2</sup> Alexander Fleming discovered penicillin in 1928. After a few years, about 50% of *Staphylococcus aureus* (*S. aureus*) infections were refractory to penicillin. Under ideal conditions, it only takes ten days for bacteria to develop resistance, and the discovery of a new antibiotic can take as little as a year or two or as long as a decade or two (Fig. 1).<sup>3</sup> Since 1990, humans have rarely discovered new antibiotic species. The world health organization (WHO) announced in September 2017 that the world's antibiotics were on the verge of depletion.

<sup>a</sup> Key Laboratory for Biobased Materials and Energy of Ministry of Education/ Guangdong Provincial Engineering Technology Research Center for Optical Agriculture, College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China. E-mail: tliuyi@scau.edu.cn; Tel: +86 20-85283313

<sup>b</sup> College of Horticulture, South China Agricultural University, Guangzhou, 510642, China

<sup>†</sup> These authors contributed equally to this work.



Baoyan Guo

Baoyan Guo received her BS degree from the Henan Institute of Science and Technology in 2013 and a master's degree from South China Agricultural University in 2017. She is pursuing a PhD degree at the College of Materials and Energy at South China Agricultural University under the supervision of Prof. Yingliang Liu. Her research interests involve the synthesis and the application of CDs in agriculture.



Guo Liu

Guo Liu received his PhD degree in food science and engineering from South China Agricultural University in 2018. During 2019–2022, he was a postdoctoral fellow at the South China Agricultural University of Tea science. His research interests focus on the function and engineering of natural active substances, and comprehensive utilization of agricultural and food by-products.



The drug resistance of pathogenic bacteria is a serious biological and environmental problem, threatening the healthy survival of human beings. People have made unremitting efforts to seek new antimicrobial materials. Nanomaterials do not easily develop drug resistance due to: (1) high membrane permeability, (2) efflux pump inhibitors, and (3) multiple antibacterial action.<sup>4,5</sup> Graphene-based nanomaterials have bactericidal properties,<sup>6–8</sup> but they can affect the DNA and mitochondrial activity of cells, leading to apoptosis,<sup>9</sup> and some nanomaterials exhibit biological toxicity toward bacteria and human cells.<sup>10</sup>

Carbon dots (CDs) are 0-dimensional spherical luminescent nanoparticles with a size of <10 nm. The structure of CDs is usually composed of an sp<sup>2</sup>/sp<sup>3</sup> carbon core and a shell with a large number of functional groups/polymer chains on the surface. The existence of surface functional groups makes CDs easily functionalized and have good solubility. CDs are mainly divided into carbon nanodots (CNDs), carbon quantum dots


(CQDs), graphene quantum dots (GQDs), and carbonized polymer dots (CPDs) according to their different structures. The core of CNDs has a graphite-like structure or amorphous form. The core of CQDs consists of a small number of graphene layers, and the layer spacing is 0.34 nm, corresponding to the (002) plane. The number of graphene layers in GQDs is smaller, and the atomic spacing is 0.24 nm, corresponding to the (100) plane. The structure of CPDs can be formed by cross-linked polymers or by functional groups/polymer chains linked to a spherical carbon core.<sup>11–13</sup> Since CDs were discovered in 2004, due to their small size, biocompatibility, photoluminescence and easy functionalization and modification, they have been widely studied in biosensing,<sup>14</sup> bioimaging,<sup>15,16</sup> photothermal and photodynamic diagnosis and treatment,<sup>17–20</sup> antibacterial nanomaterials,<sup>21,22</sup> targeted drug delivery,<sup>23–26</sup> and other aspects. In addition to top-down and bottom-up synthesis, researchers have isolated CDs from systems where Maillard reactions occurred in coffee, barbecue, and beer.<sup>27</sup> The antimicrobial properties of CDs continue to attract the attention of researchers. The antibacterial mechanism of CDs is different from traditional antibiotics, and CDs are not prone to drug resistance. The different antimicrobial effects of CDs are mainly related to their physical and chemical properties. Due to the different preparation methods such as precursors and synthetic conditions, CDs with different structures have different antimicrobial properties.<sup>28</sup> CDs combined with precious metal ions (silver, gold) have a strong antimicrobial ability,<sup>29,30</sup> but after antimicrobial action, the metal ions are released, which are toxic to the target. Also, the cost of precious metals is very high. Hydrogen peroxide and light-assisted CDs also exhibit antimicrobial activities<sup>17</sup> but require the help of external forces, resulting in limited conditions and scope of use. Generally, the antimicrobial ability of commonly synthesized CDs is limited.

Generally, the physicochemical properties are adjusted by changing the synthetic precursor, purification method, and surface functionalization, thereby improving the antimicrobial



**Chaofan Hu**

*Chaofan Hu received his BS degree from Hebei Polytechnic University in 2007 and MS degree from South China Normal University in 2010 and obtained his PhD degree from Jinan University in 2013 and then joined the Taiyuan University of Technology as a lecturer. Currently, he is an associate professor at South China Agricultural University. His research interests are the synthesis of luminescent nanomaterials and their bio-applications.*



**Bingfu Lei**

*Bingfu Lei received his BS and MS from the department of chemistry at Jinan University, and a PhD degree from the Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy Sciences. After graduation, he worked as a postdoctoral fellow at Osaka University for two years. He is a professor at the college of materials and energy at South China Agricultural University. His research interests include*

*phosphors, carbon dots, and silicon dot materials together with their applications in plant growth, lighting, biolabeling, and sensing.*



**Yingliang Liu**

*Yingliang Liu received his master's degree from the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences in 1989 and his doctor's degree from Zhongshan University in 1994. He has been engaged in the research on functional materials and carbon nanomaterials. His main research directions are: photofunctional materials: exploration of new luminescent materials, optical properties and their applications in agriculture and energy fields and the design, preparation, photoelectric properties and application of biomass carbon materials in energy and agriculture.*






Fig. 1 The timeline of antibiotics development and the subsequent emergence of resistant microorganisms (reprinted from ref. 3, with permission from Elsevier).

performance.<sup>21</sup> Researchers have reviewed synthetic precursors of antimicrobial CDs and the structure of CDs, but there have been no discussions on the relationship between the structural characteristics and antimicrobial activity.<sup>31</sup> So, what structure of CDs exhibits a better antimicrobial effect? Do CDs have specific antimicrobial effects on different types of microorganisms? What is the antimicrobial mechanism of CDs for different types of microorganisms? In view of the above questions, this paper will review the previous work of researchers and summarize the relationship between the structural characteristics of pure CDs and the antimicrobial effect, as well as the antimicrobial mechanism of different microbial types, so as to make contributions to the preparation of antimicrobial CDs in the future and its application in agricultural products.

## 2. Structural characteristics of CDs with antimicrobial properties

### 2.1. Size and shape


The size distribution of antimicrobial CDs is mostly less than 5 nm. Research results showed that the smaller size of the CDs was conducive to entering and exiting the cell and exhibited their antimicrobial ability. Positively charged large ( $5.3 \pm 0.5$  nm), medium ( $3.9 \pm 0.6$  nm), and small ( $2.0 \pm 0.3$  nm) CDs were synthesized using chlorhexidine gluconate as a precursor.<sup>32</sup> They exhibited significant antibacterial activity against the Gram-negative bacteria *Escherichia coli* (*E. coli*) and Gram-positive bacteria *S. aureus*. The antibacterial mechanism was to increase the cell permeability and destroy the integrity of the plasma membrane. It was found that CDs with a smaller size exhibited a stronger antibacterial activity (Fig. 2A). The authors believed that the reason for this may be the difference in the distribution or entry of CDs on the plasma membrane or the interaction between the surface functional groups of the CDs and DNA molecules.

The thickness of the passivation layer on the surface of the CDs had an effect on the antibacterial effect. Rabe *et al.* prepared CDs with different surface functionalities to study their photodynamic antibacterial activity.<sup>33</sup> CDs with different surface passivation layer thicknesses were prepared with PEI of different molecular weights. The results showed that smaller molecular weight resulted in thinner CDs and stronger antibacterial activity. The authors speculated that a thinner surface passivation layer might allow the photogenerated reactive oxygen species (ROS) to act more efficiently on bacterial cells. In the above two references, although the author has adjusted the size of the CDs and the thickness of the passivation layer, the research on the specific antibacterial mechanism of CDs needs to be strengthened.

The shape of the CDs was also an important factor of its antibacterial activity. By controlling the surface Gaussian curvature of the CDs, Hui *et al.* prepared CDs matching the curvature of *S. aureus* using the  $C_{60}$  cage as a precursor.<sup>6</sup> The obtained CDs could specifically kill *S. aureus* and its antibiotic-tolerant persisters but could not kill other bacterial species and mammalian cells (Fig. 2B). The surface Gaussian curvature matching between the CDs and the target bacteria played a key role in destroying the integrity of the bacterial cell membrane, thus exhibiting the antibacterial ability.

The chiral molecule D-glutamate (D-Glu) is the basic substance for the synthesis of peptidoglycan (PG), which is catalyzed by MurD ligase. PG is an important component of bacterial cell walls, but not mammalian cells, and protects them from damage caused by a high internal osmotic pressure.<sup>34</sup> Chirality can be transferred from chiral molecules to achiral nanomaterials.<sup>35,36</sup> Through the synthesis of chiral CDs (DGG), which compete with D-Glu to bind MurD, the formation of an intact cell wall could be inhibited to achieve the specific elimination of Gram-positive and Gram-negative bacteria while maintaining the integrity of mammalian cells (Fig. 2C).<sup>37</sup> The van der Waals and hydrogen bond interaction between DGG and MurD was stronger than that between LGG and MurD, which resulted in a higher inhibitory effect of DGG.





**Fig. 2** Antibacterial diagram of CDs with different sizes and shapes. (A) Schematic diagram of the antibacterial effect of CDs with different sizes (reprinted from ref. 32, with the permission of Elsevier). (B) Schematic diagram of how the surface curvature matching between GQD and the target bacterial surface correlates with the antibacterial performance of GQD (reprinted from ref. 6, with the permission of American Chemical Society). (C) The antibacterial strategies of chiral nanoparticles (DGG) (reprinted from ref. 37, with the permission of Wiley-VCH).


## 2.2. Surface charge

Different surface groups of the CDs result in different surface charges and, thus, different antimicrobial properties. Generally, as the charge on the surface of the CDs (measured by a zeta potentiometer) becomes more positive, the antimicrobial ability becomes stronger.<sup>38,39</sup> Because the cell membrane was negatively charged, the antimicrobial mechanism of the positively charged nanoparticles was the destruction of the cell membrane integrity.<sup>40,41</sup>

Bing *et al.* prepared positively charged SC-CDs (27.6 mV), negatively charged CC-CDs (−19.5 mV), and neutrally

charged GC-CDs (0.946 mV) to compare the effects of the different charge of the CDs on the antibacterial activity directly.<sup>38</sup> The SC-CDs showed the best resistance to *E. coli* at 300  $\mu\text{g mL}^{-1}$ . The antibacterial mechanism was to induce ROS aggregation *in vivo*, induce cell apoptosis, and destroy the integrity of the bacterial cell membrane, which leads to programmed bacterial death (Fig. 3A). It is worth noting that the same CDs have different zeta potentials under different solution environmental conditions. Also, when the zeta potential of the system is below  $\pm 30$  mV, it is unstable.





**Fig. 3** (A) Schematic diagram of programmed bacterial cell death induced by CDs with different surface charges (reprinted from ref. 38, with the permission of Wiley-VCH). (B) Schematic diagram of Spd-CQD synthesis. (C) Representative images of MRSA infected wounds treated on different days (B and C reprinted from ref. 42, with the permission of Wiley-VCH). (D) Schematic diagram of CQD<sub>Spds</sub> synthesis and treatment of *S. aureus*-induced bacterial keratitis. (E) Schematic diagram of CQD<sub>Spds</sub> inducing the opening of tight junctions of corneal epithelial cells for cell side transport ((D and E) reprinted from ref. 39, with the permission of American Chemical Society). (F) Synthesis of CDs and selective staining for dead *S. aureus* (reprinted from ref. 47, with the permission of Royal Society of Chemistry). (G) Co-located fluorescence images of Si-CDs and PI in different types of dead cells at a concentration of 20 μg mL<sup>-1</sup>. (H) Imaging stability of Si-CDs and PI in *S. aureus* cells (G and H) reprinted from ref. 51, with the permission of Elsevier).



Li *et al.* prepared CDs with a high positive charge (+60.6 mV) using ammonium citrate and spermidine as precursors in a two-step method (Fig. 3B). They had antibacterial activity against non-multidrug resistant bacteria (*E. coli*, *S. aureus*, *Bacillus subtilis*, *Pseudomonas aeruginosa*) and multidrug resistant bacteria (methicillin-resistant *S. aureus* (MRSA)).<sup>42</sup> The minimum inhibitory concentration (MIC) was lower (>25 000-fold) than that of spermidine. Further studies showed that the CDs were antibacterial not by inducing ROS production but due to the high positive charge on the surface of CDs, binding with proteins, porins, or peptidoglycan on the cell membrane through hydrogen bonds and electrostatic interaction, resulting in synergistic cell membrane damage or inhibition of membrane synthesis. The CDs could promote wound healing in rats infected with MRSA, with better epithelialization and collagen fiber formation (Fig. 3C).

Subsequently, their research group in the above research example further improved the preparation method and obtained super-cationic CQDSpds with a small size (6 nm) and high positive charge (+45 mV) by a one-step pyrolysis method using spermidine as the precursor.<sup>39</sup> The CQDSpds also showed antibacterial activity against both non-multidrug resistant bacteria and multidrug resistant bacteria (Fig. 3D). The CQDSpds had a strong disintegration effect on bacterial membranes. In addition, in the BK rabbit model, the formulation of topical eye drops made by CQDSpds was shown to be more effective than Ag NPs in treating *S. aureus* eye infections because the super-cationic CQDSpds induced the opening of tight junctions in corneal epithelial cells for cellular side transport (Fig. 3E).

CDs with a high positive charge can fight viruses as well as bacteria. Researchers synthesized positively charged (15.6 ± 2.05 mV) CDs with curcumin as the precursor to resist porcine epidemic diarrhea virus (PEDV) infection, and the positively charged CDs may lead to viral aggregation through electrostatic interaction, thus reducing viral infectivity.<sup>43</sup>

However, it is not just the positively charged CDs that are antibacterial. Some negatively charged CDs have been reported to have antimicrobial activity. When CDs with a high negative surface charge (−75 ± 4 mV) were used to treat *S. aureus* and MRSA, they showed better antibacterial activity under laser irradiation.<sup>44</sup> According to the report, it was because the van der Waals force between the highly negatively charged CDs and the bacteria could overcome the weak repulsive force,<sup>45</sup> which made the CDs adhere to the cell surface, resulting in the production of ROS and cell wall damage, protein structure and function changes, and subsequently the death of the bacteria. However, some reports differ from these mechanisms. Zhu *et al.* prepared antibacterial CDs with a negative charge (−30 mV) by the electrolytic method using a vitamin C solution as the electrolyte.<sup>46</sup> The CDs prevented the formation of the bacterial biofilm through electrostatic repulsion, and it might cover the outer surface of bacterial cells. Due to biological isolation, bacterial cells could neither increase in value nor consume nutrients after separation, thus damaging the cell wall or cell membrane to achieve the antibacterial effect.

Other negatively charged CDs showed a different result; that is, as the CDs become more negatively charged, the imaging ability is better, which makes them useful as an alternative dye to identify dead and live cells.<sup>47–50</sup> Hua *et al.* for the first time used bacteria as the precursor to prepare CDs with a high negative charge (−42 mV) for differentiating live/dead cells (bacteria and fungi) (Fig. 3F).<sup>47</sup> Compared with the conventional commercial dye propidium iodide (PI), CDs show advantages such as low toxicity, polychromatic imaging, and stability. This broadens the selection of raw materials for the preparation of CDs. Subsequently, using yeast extract as the precursor, CDs (−41.9 mV) with the ability to selectively stain dead bacteria were prepared, and when co-cultured with living bacteria, the bacterial activity could be monitored in real time with the increase in temperature.<sup>48</sup> Similar results have also been reported.<sup>49</sup> Silanized CDs with a small size (~2.8 nm) and high fluorescence quantum yield (~93.23%) were prepared by our group.<sup>51</sup> They can stain bacterial, fungal, and mammalian dead cells in a passive diffusion manner (Fig. 3G) and have a lower cytotoxicity and better photostability than commercial staining (PI) (Fig. 3H).

### 2.3. Heteroatomic doping

Generally, N-doped CDs exhibit a strong antibacterial ability because N doping may endow CDs with positively charged properties<sup>52</sup> or a lower band gap energy,<sup>53</sup> which can exert antibacterial effects.

The effect of S and N-doped CDs prepared by Travlou *et al.* was better on Gram-positive bacteria than on Gram-negative bacteria, and the minimum inhibitory concentration (MIC) was equal to or smaller than some antibiotics or silver nanoparticles.<sup>54</sup> The antibacterial activity of N-CQDs was stronger than that of S-CQDs, mainly because the protonation of the nitrogen functional group of N-CQDs acted with the negatively charged cell membrane to generate ROS, which induced bacterial cell death. The negatively charged S-CQDs showed inhibition of bacterial growth due to the small size rather than the chemical dependence.

Wang *et al.* synthesized Cl-doped CDs with dual characteristics of anti-oxidation and pro-oxidation by the electrochemical method, and their free radical scavenging and free radical generation abilities were seven times and three times higher than those of undoped CDs, respectively.<sup>55</sup> This was attributed to the high content of defect sites caused by Cl doping, which enabled them to produce ROS under visible light irradiation. This was considered a promising antibacterial application (Fig. 4A). However, the study would be more complete if there were comparisons with the antimicrobial activity of CDs doped with other elements.

N-Doped CDs prepared with bis-quaternary ammonium salt as the precursor had a high antibacterial activity toward drug resistant bacteria.<sup>52</sup> It can kill MRSA without producing drug resistance, prevent the formation of a biofilm, and eliminate the formed biofilm and persistent cells. The N-CD treatment fought bacterial infection and sped up the wound healing. Because N-CDs have a positive charge, they could cause cell






Fig. 4 (A) Schematic diagram of CI-GQDs with both anti-oxidation and pro-oxidation properties (reprinted from ref. 55, with the permission of American Chemical Society). (B) Schematic diagram of N-CQDs for antibacterial and disperse bacterial biofilms (reprinted from ref. 52, with the permission of American Chemical Society). (C) Schematic diagram of the photocatalytic mechanism of CQD doped with different elements. CB and VB are the conduction band and valence band, respectively (reprinted from ref. 53, with the permission of Elsevier).

membrane damage and increase the permeability through electrostatic interactions, induce the generation of ROS, and further affect bacterial metabolism, leading to death (Fig. 4B).

Doping CDs can change their structure and composition, essentially change their electronic properties or energy state, and then improve their optical properties and application performance.<sup>56,57</sup> Recent studies have shown that CDs doped with N and/or S exhibited a vision-driven antimicrobial activity<sup>53</sup> because doped N and/or S reduced the gap between the valence band and the conduction band of CDs compared with undoped CDs (Fig. 4C) and increased the electron density near the conduction band by supplying electrons to CDs through lone pair electrons of N or S.<sup>58–60</sup> However, N-doping could improve the antibacterial performance of CDs better than NS-doping because with the increasing ratio of S, the CDs became not conducive to ROS generation and the specific surface area increased, resulting in the reduction in the

reaction sites. The decrease in the fluorescence quantum yield led to adverse radiation recombination, and the decrease in the fluorescence lifetime made the photoexcitation state unable to be maintained well.<sup>53</sup>

## 2.4. Surface functionalization

### 2.4.1 Quaternization.


Quaternary ammonium compounds (QACs) have been reported to have activity against Gram-positive bacteria by directly destroying microbial cell membranes, which makes it difficult for bacteria to develop drug resistance.<sup>61–63</sup> CDs have excellent optical performance. Combining QACs on the surface of CDs can not only realize the imaging and classification of bacteria but also significantly reduce the MIC of drugs.<sup>64</sup>

CDs prepared with glucose and PEI as precursors and subsequently quaternized with benzyl bromide have an inhibitory effect on Gram-positive and Gram-negative bacteria.<sup>65</sup>



This was due to the adsorption of quaternized CDs on cell membranes, causing their destruction. Quaternized CDs were prepared by conjugating lauryl betaine (BS-12) containing a quaternary ammonium group onto the surface of CDs.<sup>64</sup> The quaternized CDs have the ability to resist Gram-positive bacteria and selectively stain Gram-positive bacteria. Compared with BS-12, the local positive charge density and hydrophobic chain number of the quaternary ammonium CDs increased, which enhanced the antibacterial ability (Fig. 5A).

The QACs can not only bind to the surface of CDs and play an antibacterial effect but can also be used as a precursor to undergo a solvothermal reaction with chloroform and diethylamine to generate CDs with a positive surface charge.<sup>66</sup> Then, the as-prepared CDs interacted with the negatively charged cell membrane to resist Gram-positive and Gram-negative bacteria. Yang *et al.* prepared quaternized CDs by the solvent-thermal method with glycerol and dimethyloctadecyl [3-(trimethoxysilyl) propyl] ammonium chloride (Si-QAC) as the precursor.<sup>67</sup> The as-prepared CDs can selectively interact with Gram-positive



**Fig. 5** (A) Schematic diagram of CDs-C12 preparation and selective killing and staining of Gram-positive bacteria (reprinted from ref. 64, with the permission of American Chemical Society). (B) Schematic diagram of quaternary ammonium CDs in the imaging, eradication, and inhibition of *S. aureus* biofilms (reprinted from ref. 68, with the permission of Royal Society of Chemistry). (C) Preparation, antibacterial properties, and antibacterial mechanism of quaternary ammonium QCQD and its application in MRSA induced pneumonia in mice (reprinted from ref. 69, with the permission of Elsevier).





bacteria through electrostatic and hydrophobic interactions, inserting long alkyl chains into the bacterial surface and eventually inactivating the Gram-positive bacteria. Subsequently, they synthesized quaternary ammonium CDs without long alkyl chains and verified that the long alkyl chain enhanced the hydrophobic adhesion between CDs and Gram-positive bacteria. They further showed that cationic CDs inhibited the formation of Gram-positive bacteria biofilms (Fig. 5B).<sup>68</sup>

Zhao *et al.* prepared quaternary ammonium CDs that had good antibacterial activity against Gram-positive bacteria including MRSA and could promote inflammation subside in pneumonia mice infected with MRSA.<sup>69</sup> Further proteomic studies showed that the antimicrobial mechanism of these CDs was action on ribosomes and upregulation of RNA degradation related proteins, thus interfering with protein translation and modification in bacterial cells (Fig. 5C). Then, the quaternary ammonium CDs prepared by a one-step solvothermal method using *p*-phenylenediamine as the precursor were reported to have antibacterial activity against Gram-positive bacteria (*S. aureus*) and Gram-negative bacteria (*E. coli*), and the minimum inhibitory concentrations were 2 and 30  $\mu\text{g mL}^{-1}$ , respectively.<sup>70</sup> The results showed that a large number of  $-\text{NH}_3^+$  groups on the surface of the CDs enhanced their antibacterial activity. It is worth noting that quaternary ammonium salts themselves have anti-viral and antibacterial effects, so attention should be paid to the purification of CDs when preparing such CDs.

**2.4.2 Surface modification of antibacterial agents.** CDs prepared with antibiotics or antibacterial components as a precursor or CDs combined with them usually have a better antibacterial performance. In 2013, Thakur *et al.* prepared CDs from gum arabic and combined them with the antibiotic ciprofloxacin hydrochloride to obtain CDs with antibacterial activity against both Gram-positive and Gram-negative bacteria.<sup>71</sup> Subsequently, Hou *et al.* in 2017 prepared CDs with antibacterial activity against Gram-positive and Gram-negative bacteria by a one-step method using ciprofloxacin hydrochloride as a precursor.<sup>72</sup> They proposed that the functional structure of the precursor could be maintained if the reaction temperature was lower than the decomposition temperature of ciprofloxacin hydrochloride. Studies showed that whether penicillin was used as a precursor to prepare CDs or covalently combined with  $-\text{NH}_2$  containing citric acid-based CDs, the obtained CDs showed antimicrobial activity to both resistant and non-resistant bacteria under visible light but had little effect on the cell viability of mammalian cells.<sup>73</sup> Similarly, ampicillin was conjugated with amine-terminated CDs. The obtained CDs not only retained the inherent chemical properties of CDs- $\text{NH}_2$  but also employed the antibacterial properties of ampicillin to produce ROS under light and had antibacterial activity against *E. coli*.<sup>74</sup> Selective antibiotics are more acceptable than broad-spectrum antibiotics. Using metronidazole as a precursor, CDs with selective resistance to obligate anaerobes *Porphyromonas gingivalis* were obtained.<sup>75</sup> Additionally, the combination of CDs and other antibacterial components could

reduce the amount of antibacterial components used alone, reducing the risk to the environment and the resistance of microorganisms.<sup>76</sup>

## 2.5. Other antibacterial CDs

With natural biomass as the precursor, CDs with antibacterial activity have been prepared. Zhao *et al.* prepared CDs with banana as the precursor and combined with chitosan to form a coating solution, which could prolong the shelf life of soy milk and significantly reduce the total bacterial count after 4 days of storage at room temperature.<sup>77</sup> Using the natural biomass *Artemisia argyi* leaves, Wang *et al.* prepared CDs with 100% antibacterial activity against Gram-negative bacteria at a concentration of 150  $\mu\text{g mL}^{-1}$  by a smoking simulation method.<sup>78</sup> The prepared CDs could affect the secondary structure of the enzyme related to the cell wall synthesis of bacteria and, thus, inhibit about 50% of the enzyme activity, thereby selectively resisting the activity of Gram-negative bacteria.

CDs were reported to have broad-spectrum antibacterial activity against Gram-positive (*S. aureus* and *B. subtilis*), Gram-negative (*Bacillus* sp. WL-6 and *E. coli*), fungi (*R. solani* and *P. grisea*), and drug-resistant bacteria (the ampicillin-resistant *E. coli*).<sup>79</sup> The optimal inhibitory concentration was 100  $\mu\text{g mL}^{-1}$  for bacteria and drug-resistant bacteria and 300  $\mu\text{g mL}^{-1}$  for fungi. The research group then used cigarette smoke to prepare biodegradable CDs that were also broad-spectrum resistant to Gram-positive and Gram-negative bacteria, as well as drug-resistant bacteria.<sup>80</sup>


## 3. The antimicrobial mechanism of CDs

Although some CDs have a broad spectrum of antimicrobial properties, they can fight various types of bacteria, fungi, drug-resistant bacteria, multi-resistant bacteria, and even viruses. But overall, bactericidal targeting of specific bacteria is a promising treatment for infections, as it minimizes side effects and enhances antimicrobial activity.<sup>81</sup> Therefore, it is necessary to summarize the types of microorganisms and the antimicrobial mechanism of CDs, so as to guide the purposeful synthesis of CDs.

### 3.1. The mechanism of CDs against bacteria

The cell wall of bacteria can maintain the cell shape, improve mechanical strength, inhibit damage, assist cell movement and growth, and provide sensitivity to antibiotics. According to its form and function, it can be divided into Gram-positive and Gram-negative bacteria. The cell wall of Gram-positive bacteria consists mainly of thick layers of peptidoglycan and acidic polysaccharides including teichoic acid (Fig. 6A), and the overall negative charge on the cell surface is partly due to teichoic acid.<sup>82</sup> The cell wall of Gram-negative bacteria, on the other hand, is more complex, consisting of thin monolayers of peptidoglycan and an outer membrane that includes porin and lipopolysaccharide (Fig. 6B).<sup>83</sup> Different types of bacteria





**Fig. 6** Cell walls of bacterial. The cell wall of Gram-positive (A) bacteria consists of multiple layers of thick polypeptidoglycan (PG) sheaths. Teichoic acid was embedded in PG, while lipoteichoic acid extended into the cytoplasmic membrane. The cell wall of Gram-negative (B) bacteria consists of an outer membrane connected by lipoproteins to a thin monolayer of PG. PG is placed in the periplasmic space formed by the outer and inner membranes. The outer membrane contains pores and lipopolysaccharide molecules ((A and B) reprinted from ref. 83, with the permission of Springer Nature).

have different mechanisms of drug resistance. Gram-negative bacteria (*E. coli*) can change the nature of their cell walls so that they are not recognized by antibiotics, thus limiting the entry of antibiotics into their outer membranes.<sup>84</sup> Gram-positive bacteria (*K. pneumoniae* and *S. aureus*) produce enzymes that destroy antibiotic molecules.<sup>85</sup>

Quaternary ammonium polymers and compounds have strong bactericidal activity against Gram-positive bacteria. Generally, CDs with a positive surface charge approach bacteria with a negative surface charge through electrostatic interactions. In most cases, these are Gram-positive bacteria. They induce the bacteria to produce ROS, thus causing mechanical damage to the cell membrane, destroying the integrity of the cell membrane, and inducing cytoplasm leakage and cell apoptosis. However, some studies have observed that positively charged CDs can induce Gram-negative bacteria to produce endogenous ROS, destroy the integrity of the cell membrane, and lead to cell apoptosis along with DNA fragmentation.<sup>38</sup> It is worth noting that each type of bacteria was sensitive to different free radicals. *E. coli* O157:H7 was more sensitive to  $\bullet\text{OH}$  and  $^1\text{O}_2$ , while *L. monocytogenes* was more sensitive to  $\text{H}_2\text{O}_2$  and

$^1\text{O}_2$ .<sup>53</sup> According to a report from Huang *et al.*, Gram-positive bacteria were more sensitive to  $^1\text{O}_2$ , while Gram-negative bacteria were more sensitive to  $\bullet\text{OH}$ .<sup>86</sup>

The antibacterial mechanism of CDs against bacteria involves multiple aspects: (1) causing physical and mechanical damage to the cell membrane, (2) affecting the activity of bacterial cell wall synthetases, (3) inducing cellular production of ROS, (4) disrupting cell membrane electron transport, (5) entering into the cell, affecting DNA and protein synthesis, (6) inhibiting the synthesis of bacterial biofilm, *etc.* When CDs exert antibacterial effects, it may be a single mechanism of action, or there may be a coexistence of multiple mechanisms. It is the multi-mechanism that makes CDs less likely to develop drug resistance. The antibacterial mechanisms of CDs in photodynamic therapy or photothermal therapy have been extensively reviewed<sup>14,17</sup> and will not be described here.

The structural characteristics of CDs cannot be uniformly matched with the corresponding types of resistant bacteria, mainly because most studies are based on the existing available CDs and bacterial types rather than on specific CDs and bacterial types.



### 3.2. The mechanism of CDs against fungi

The imaging application of CDs in fungal cells has been widely reported. Thakur *et al.* first combined ciprofloxacin with CDs to form a Cipro@C-dots conjugate, which could perform *in vivo* imaging of *Saccharomyces cerevisiae* (yeast) and emit bright green fluorescence.<sup>71</sup> Similar imaging of CDs in living fungi was also observed in *Valsa Mali Miyabe et Yamada*,<sup>87</sup> *Aspergillus aculeatus*,<sup>88,89</sup> *Saccharomyces cerevisiae*,<sup>90</sup> *Colletotrichum gloeosporioides*,<sup>91</sup> and *Fusarium oxysporum*.<sup>92</sup> When CDs were prepared with bacteria as a precursor, the imaging application of CDs can be observed in dead fungal cells *Saccharomyces cerevisiae* (yeast) and *Trichoderma reesei*.<sup>47</sup> Silanized CDs prepared by our group can also stain dead fungal cells (*AH109* yeast, *Penicillium italicum*).<sup>51</sup> These results suggest that CDs can enter dead or living fungal cells.

*Rhizoctonia solani* and *Pyricularia grisea* are two kinds of fungi causing plant diseases. Li *et al.* prepared biodegradable CDs with antifungal activity against the above two fungi at the concentration of 300  $\mu\text{g mL}^{-1}$ .<sup>79</sup> Further studies showed that CDs could directly enter the fungal nucleus and destroy it, inhibiting the growth of fungal cells. Moreover, CDs could significantly inhibit the expression of the non-ribosomal peptide synthase gene in *Rhizoctonia solani*. The CDs prepared with tamarind as a precursor showed antifungal activity against *Candida albicans*.<sup>93</sup> Confocal microscopy was used to observe the morphology of *Candida albicans*. The results showed that CDs could interact with fungal cells, but the antifungal mechanism was not further studied. Bagheri *et al.* reported that the prepared CDs inhibited the growth of *Pichia pastoris* in a dose-dependent manner.<sup>94</sup> At high concentrations, the CDs can significantly change the morphology of yeast cells and stimulate the production of toxic levels of ROS to inhibit the growth of yeast cells. The multi-functional CDs prepared with dried seaweed as the precursor had anti-fungal *cucumber downy mildew* (*Pseudoperonospora cubensis*) activity.<sup>95</sup> At the concentration of 40  $\text{mg L}^{-1}$ , the CDs could inhibit 20% fungal activity. With the increase in the concentration of CDs, there was no enhanced antibacterial activity. CDs loaded with flumorph exhibited better antifungal activity than CDs and flumorph alone. The authors suggest that the oxygen-containing groups on the surface of the CDs might adsorb on the fungal cell walls and destroy the integrity of the cell membrane, leading to cytoplasm leakage. However, there were no further mechanistic tests. Fungi are more stubborn than bacteria, so timeliness and dosage should also be taken into account when evaluating the activity of antifungal CDs.

### 3.3. The mechanism of CDs against virus

Most viruses can cause illness and even death in humans. The best way to prevent infection is to get vaccinated. However, there are currently no effective vaccines against the various viruses and their variants. Nanotechnology has shown powerful capabilities in antiviral strategies, and some researchers have reviewed relevant studies on the antiviral effects of functional nanoparticles and their corresponding antiviral mechanisms.<sup>96</sup>

As a new star in nanomaterials, CDs have also been studied in antiviral field. Especially since the outbreak of the novel Coronavirus (COVID-19) pandemic in 2019, more researchers have begun to focus on the study of CDs resistance toward novel Coronaviruses, and six relevant review papers have been published.<sup>97–102</sup> We have summarized thirteen published research papers about antiviral CDs, including the precursor, antiviral types, and antiviral mechanism (Table 1), in order to provide a reference for future research on antiviral CDs.

Barras *et al.* prepared boronic acid- and amine-functionalized CDs with phenylboronic acid derivatives as precursors.<sup>103</sup> The prepared CDs could prevent herpes simplex virus type 1 infection. The EC<sub>50</sub> was 80  $\text{ng mL}^{-1}$  in Vero and 145  $\text{ng mL}^{-1}$  in A549 cells, respectively. The antiviral mechanism of CDs was the inhibition of viral entry through the interaction with the viruses. Subsequently, their group prepared seven different CDs, and the results showed that the EC<sub>50</sub> of CDs prepared with ethylenediamine and citric acid as precursors and modified with boronic acid was  $52 \pm 8 \mu\text{g mL}^{-1}$ , although the presence of boronic acid was essential for antiviral activity, but CQDs-6 did not carry a large amount of boronic acid and was more antiviral with an EC<sub>50</sub> of  $5.2 \pm 0.7 \mu\text{g mL}^{-1}$ , indicating the complexity of the antiviral mechanism.<sup>104</sup> The prepared CDs exerted antiviral effects by inhibiting viral entry into receptors and inhibiting viral replication.

Amino phenylboronic acid-modified CDs prepared by Aung *et al.* showed antiviral activity against the HIV-1 virus.<sup>105</sup> The antiviral mechanism of CDs was similar to that previously reported by Barras *et al.* because CDs had boron and nitrogen on their surface, which can bind to the gp120 glycoprotein on the envelope of the HIV-1 virus, thus preventing the virus from entering the host cell.

Du *et al.* found that CDs induced the production of interferon- $\alpha$  and the expression of the IFN stimulating gene.<sup>106</sup> Thus, it can inhibit the replication of the Pseudorabies virus and Porcine reproductive and respiratory syndrome virus. Subsequently, the same authors synthesized curcumin-based CDs that antiviral enteric coronavirus through multiple inhibitory effects, including inhibition of viral entry, synthesis of viral negative strand RNA, viral budding, and accumulation of ROS.<sup>43</sup> In addition, the CDs were found to inhibit viral replication by enabling the production of pro-inflammatory cytokines and stimulating interferon-stimulated genes.<sup>43</sup> Between the two studies, the research group synthesized blue-CDs and cyan-CDs with young barley leaves and citric acid anhydrous without or with urea.<sup>107</sup> It was found that blue-CDs had a better antiviral effect than cyan-CDs because most of the factors involved in the interferon induction pathway were located in the cytoplasm, while the amount of blue-CDs in the cytoplasm was higher than that of cyan-CDs. Both of them could induce the expression of interferon and its stimulating genes.

The CDs prepared by Dong *et al.* using a two-step method showed resistance to human norovirus virus-like particles (VLPs).<sup>108</sup> The positively charged EDA-CDots are much more effective than the negatively charged EPA-CDots in inhibiting the binding of VLPs to HBGA receptors because the binding of



Table 1 The summary of reports on CDs for antiviral applications

Year	Precursor	Synthesis method	Virus species	Antiviral mechanism	Concentration
2016 <sup>106</sup>	PEG-diamine and ascorbic acid	Solid-phase thermal reaction	Pseudorabies virus, porcine reproductive and respiratory syndrome virus	Inhibiting viral replication	0.125 mg mL <sup>-1</sup>
2016 <sup>103</sup>	4-Aminophenylboronic acid hydrochloride	Hydrothermal	Herpes simplex virus type 1 (HSV-1)	Inhibiting virus entry	EC50 = 80 and 145 ng mL <sup>-1</sup> on Vero and A549 cells, respectively
2017 <sup>107</sup>	Barley young leaves, citric acid anhydrous and urea	Solid pyrolysis	Pseudorabies virus	Inhibiting viral replication	0.13 mg mL <sup>-1</sup>
2017 <sup>108</sup>	Carbon nano-powders, 3-ethoxypropylamine and 2,2'-Inhibiting virus entry	5 µg mL <sup>-1</sup>		(ethylenedioxy)bis(ethylamine)	Nitric acid reflux and thermal mixing
Human norovirus virus-like-particles 2018 <sup>43</sup>	Curcumin and citric acid	Solid pyrolysis	Enteric coronavirus	Various inhibitory effects including inhibition of viral entry, viral negative-strand RNA synthesis, viral budding, accumulation of ROS, and inhibition of viral replication	125 µg mL <sup>-1</sup>
2019 <sup>112</sup>	Curcumin	Dry heating	Enterovirus 71	Inhibiting the virus entry, replication, and preventing the virus-induced termination of host translation	EC50 (0.2 µg mL <sup>-1</sup> ) and CC <sub>50</sub> (452.2 µg mL <sup>-1</sup> )
2019 <sup>104</sup>	4-Aminophenylboronic acid	Hydrothermal	Human coronavirus	Inhibiting virus entry into receptor and virus replication	EC50 = 5.2 ± 0.7 µg mL <sup>-1</sup>
2019 <sup>110</sup>	Benzoxazine	Hydrothermal	Flaviviruses (Japanese encephalitis, Zika, and dengue viruses) and non-enveloped viruses (porcine parvovirus and adenovirus-associated virus)	Preventing the virion from entering the host cell	75 µg mL <sup>-1</sup>
2019 <sup>111</sup>	Humic acid	Hydrothermal	Avian leukosis virus subgroup J	As an excellent adjuvant of the gp85 protein vaccine against chicken anti-avian leukosis virus subgroup J	400 µg mL <sup>-1</sup>
2020 <sup>114</sup>	Glycyrrhizic acid	Hydrothermal	Porcine reproductive and respiratory syndrome virus (PRRSV), pseudorabies virus (PRV), and porcine epidemic diarrhea virus (PEDV)	Inhibiting virus invasion and replication, stimulating the production of interferons, inhibiting the accumulation of intracellular ROS, regulating the expression of some host-restricted factors (ethylenedioxy)bis(ethylamine)	0.30 mg mL <sup>-1</sup>
2020 <sup>109</sup>	Carbon nano-powders, 2,20-Viral protein carbonylation and degradation of viral genomic RNA	20 µg mL <sup>-1</sup>			Nitric acid reflux and thermal mixing
2020 <sup>113</sup>	Spermidine trihydrochloride	Pyrolysis	White spot syndrome virus	Sticking to virus envelope and inhibiting virus infection, upregulating immune genes and reducing the mortality rate of virus infection	10 ppm
2020 <sup>105</sup>	Anhydrous citric acid and 2-amino phenylboronic acid	Pyrolysis	HIV-1	Preventing the virus from entering the host cell	50 µg mL <sup>-1</sup>

EDA-CDots to negatively charged VLPs is more favorable. The main antiviral mechanism of CDs is to effectively inhibit the binding of VLPs to HBGA receptors and moderately inhibit the binding of VLPs to antibodies without affecting the integrity of viral capsid proteins and virus particles. Then, their group studied the photodynamic antiviral activity of EDA-CDots under visible light irradiation using bacteriophages MS2 as a virus model.<sup>109</sup> The results showed that the CDs caused carbonylation of viral proteins and degradation of genomic RNA.

CDs synthesized by benzoxazine as a precursor were reported to have spectral antiviral activity.<sup>110</sup> The antibacterial mechanism was the direct interaction of CDs with viruses to prevent viruses from entering host cells and to limit the spread of the viruses. It was reported that CDs prepared with humic acid as a precursor can be used as an excellent adjuvant of the chicken gp85 protein vaccine against avian leukosis virus subgroup J.<sup>111</sup> Antibody levels in the gp85-CDs group were higher than those in the gp85-Freund adjuvant group.



CDs prepared using curcumin as a precursor by the dry heating method had antiviral activity against enterovirus 71.<sup>112</sup> The results showed that CDs inhibited the virus by binding to the virus, prevented the virus from attaching to the host cell membrane, inhibited viral replication, and prevented the virus-induced termination of host translation. The polyamine CDs mentioned above can destroy bacterial cell membranes due to its high positive charge, thus having antibacterial activity, and can treat bacterial infection in rabbit eyes.<sup>39</sup> The authors then treated the white spot syndrome virus, which is an envelope virus, with the same CDs and found that the CDs could disrupt the envelope of the virus, thus affecting the invasion of the virus. In addition, the CDs also upregulated immune genes and reduced the mortality of infected mice.<sup>113</sup> CDs synthesized from glycyrrhizic acid, the active ingredient of Chinese herbal medicine, has been reported to have anti-porcine reproductive and respiratory syndrome virus (PRRSV) activity.<sup>114</sup> The antiviral mechanisms of CDs were to inhibit the invasion and replication of PRRSV, stimulate the production of interferon, inhibit the accumulation of intracellular ROS caused by PRRSV infection, and regulate the expression of some host-restricted factors directly related to the proliferation of PRRSV, including DDX53 and NOS3. It can be seen from the above results that CDs prepared from natural substances have high biocompatibility, and the prepared CDs can inherit the antiviral properties of the precursor and have better effects and fewer side effects.

## 4. Concluding remarks

This paper reviews the current literature on CDs against bacteria, fungi, and viruses and summarizes the structural characteristics of CDs with antimicrobial effects. Although antimicrobial CDs are a developing field, the summary of this paper lays a foundation for future studies on the synthesis or optimization of antimicrobial CDs. Due to the unclear structure and chemical formula of CDs, their controllable and efficient synthesis still needs to be worked on. However, compared with other carbon materials, CDs possess advantages such as good biocompatibility, inexpensive and readily available synthetic materials, simple synthetic methods, and easy large-scale synthesis. At present, there are commercial products of CQDs on the market (<https://www.pkuchemqd.com/c/35.html>). It is believed that with the advancement of technology, the commercial production of antimicrobial CDs will soon be realized. By adjusting the size, surface charge, and doping atoms of CDs, the prepared CDs can have strong antibacterial properties. Compared with broad-spectrum resistance, precise antimicrobial properties have more advantages in reducing drug side effects and reducing drug-resistant bacteria. Therefore, we summarize the antimicrobial mechanisms of CDs for different types of microorganisms and look forward to helping the useful synthesis of antimicrobial CDs.

CDs with a small size, that can easily enter and exit cells, show better antimicrobial ability. A thinner surface passivation layer of CDs might allow photogenerated ROS to act more

efficiently on bacterial cells. The surface Gaussian curvature matching between the CDs and the target bacteria plays a key role in destroying the integrity of the bacterial cell membrane. Through the synthesis of chiral CDs, which compete with D-Glu to bind MurD, the formation of the intact cell wall could be inhibited to achieve the specific elimination of Gram-positive and Gram-negative bacteria while maintaining the integrity of mammalian cells. Because the bacterial cell membrane is negatively charged, CDs with a high positive charge easily adhere to the bacterial cell membrane and generate ROS, thus destroying the integrity of the cell membrane, leading to cytoplasmic leakage and bacterial cell death. N doping may endow CDs with positively charged properties or a lower band gap energy, which can exert antibacterial effects. Quaternized CDs have good antibacterial effects, while negatively charged CDs can be used to stain dead cells. The antibacterial properties of CDs doped with other different elements require more extensive and in-depth studies. CDs prepared with antibiotics as precursors or CDs grafted with antibiotics have good antibacterial effects, but it is necessary to pay attention to the purification steps in the preparation of CDs to exclude the antibacterial effects of the precursors themselves. CDs appear to have greater antiviral potential. The antiviral mechanisms of CDs are as follows: (1) inhibition of viral entry, (2) inhibition of viral negative-strand RNA synthesis, (3) inhibition of viral budding, (4) accumulation of ROS, (5) inhibition of viral replication, (6) upregulation of immune genes and reduction of the mortality rate of virus infection, and (7) prevention of the virus from entering the host cell. However, the high standards of the experimental conditions for infectious viruses limit their research. Future research needs to focus on the purposeful synthesis of CDs targeting specific types of microorganisms. The long-term biological toxicity of CDs has not been systematically studied. The antifungal and anti-phytopathogenic aspects of CDs are understudied.

There are currently no data on the clinical application and toxicity of CDs as antibiotics themselves. Before antimicrobial products of CDs can be used clinically, some challenges must be addressed, such as: (1) achieving targeted delivery and preventing shielding by the human/animal immune system or digestive system before reaching the site of action, (2) side effects on the human/animal body after passing through the blood–brain barrier, (3) toxicology test, (4) drug resistance test against bacteria, *etc.* In the era of antibiotic resistance, the development of safe, effective, low-side effect, and specific antibacterial agents requires interdisciplinary knowledge and tools in materials science, biology, immunology, pathology, and pharmacology. The summary of this paper is conducive to the purposeful synthesis of CDs with antimicrobial properties in the future and also lays a foundation for the application of CDs in the fields of medical materials, agricultural production, and food preservation.

## Author contributions

Baoyan Guo and Guo Liu conceived the idea and initiated the project. Baoyan Guo and Guo Liu mainly wrote the manuscript



and produced the figures. Chaofan Hu and Bingfu Lei contributed to parts of the manuscript. Yingliang Liu supervised the project and edited the manuscript. All the authors contributed to the discussion.

## Conflicts of interest

The authors declare that they have no conflict of interest.

## Acknowledgements

The present work was financially supported by the National Natural Science Foundation of China (Grant No. 12174119 and 52172142), and the Science and Technology Program of Guangzhou, China (Grant No. 202103000059).

## References

- 1 T. Yu, G. Jiang, R. Gao, G. Chen, Y. Ren, J. Liu, H. C. van der Mei and H. J. Busscher, *Expert Opin. Drug Delivery*, 2020, **17**, 1151–1164.
- 2 D. I. Andersson and D. Hughes, *FEMS Microbiol. Rev.*, 2011, **35**, 901–911.
- 3 A. J. Huh and Y. J. Kwon, *J. Controlled Release*, 2011, **156**, 128–145.
- 4 M. J. Hajipour, K. M. Fromm, A. Akbar Ashkarran, D. Jimenez De Aberasturi, I. R. D. Larramendi, T. Rojo, V. Serpooshan, W. J. Parak and M. Mahmoudi, *Trends Biotechnol.*, 2012, **30**, 499–511.
- 5 Q. Xin, H. Shah, A. Nawaz, W. Xie, M. Z. Akram, A. Batool, L. Tian, S. U. Jan, R. Boddula, B. Guo, Q. Liu and J. R. Gong, *Adv. Mater.*, 2019, **31**, 1804838.
- 6 L. Hui, J. Huang, G. Chen, Y. Zhu and L. Yang, *ACS Appl. Mater. Interfaces*, 2016, **8**, 20–25.
- 7 W. Hu, C. Peng, W. Luo, M. Lv, X. Li, D. Li, Q. Huang and C. Fan, *ACS Nano*, 2010, **4**, 4317–4323.
- 8 H. Ji, H. Sun and X. Qu, *Adv. Drug Delivery Rev.*, 2016, **105**, 176–189.
- 9 T. Lammel, P. Boisseaux, M. Fernández-Cruz and J. M. Navas, *Part. Fibre Toxicol.*, 2013, **10**, 27.
- 10 O. Bondarenko, K. Juganson, A. Ivask, K. Kasemets, M. Mortimer and A. Kahru, *Arch. Toxicol.*, 2013, **87**, 1181–1200.
- 11 C. Xia, S. Zhu, T. Feng, M. Yang and B. Yang, *Adv. Sci.*, 2019, **6**, 1901316.
- 12 P. Koutsogiannis, E. Thomou, H. Stamatidis, D. Gournis and P. Rudolf, *Adv. Phys.: X*, 2020, **5**, 1758592.
- 13 M. Varghese and M. Balachandran, *J. Environ. Chem. Eng.*, 2021, **9**, 106821.
- 14 F. Lin, Y. Bao and F. Wu, *C-J Carbon Res.*, 2019, **5**, 33.
- 15 G. Gao, Y. Jiang, W. Sun and F. Wu, *Chin. Chem. Lett.*, 2018, **29**, 1475–1485.
- 16 L. Ansari, S. Hallaj, T. Hallaj and M. Amjadi, *Colloids Surf., B*, 2021, **203**, 111743.
- 17 B. Wang, H. Song, X. Qu, J. Chang, B. Yang and S. Lu, *Coordin. Chem. Rev.*, 2021, **442**, 214010.
- 18 X. Dong, W. Liang, M. J. Meziari, Y. Sun and L. Yang, *Theranostics*, 2020, **10**, 671–686.
- 19 M. Kováčová, E. Apitalská, Z. Markovic and Z. Apitálský, *Part. Part. Syst. Charact.*, 2020, **37**, 1900348.
- 20 R. Knoblauch and C. D. Geddes, *Materials*, 2020, **13**, 4004.
- 21 M. Varghese and M. Balachandran, *J. Environ. Chem. Eng.*, 2021, **9**, 106821.
- 22 M. Alavi, E. Jabari and E. Jabbari, *Expert Rev. Anti-Infect. Ther.*, 2021, **19**, 35–44.
- 23 P. Namdari, B. Negahdari and A. Eatemadi, *Biomed. Pharmacother.*, 2017, **87**, 209–222.
- 24 M. Farshbaf, S. Davaran, F. Rahimi, N. Annabi, R. Salehi and A. Akbarzadeh, *Artif. Cells, Nanomed. Biotechnol.*, 2018, **46**, 1331–1348.
- 25 Z. Peng, X. Han, S. Li, A. O. Al-Youbi, A. S. Bashammakh, M. S. El-Shahawi and R. M. Leblanc, *Coordin. Chem. Rev.*, 2017, **343**, 256–277.
- 26 Z. Wang, Z. Wang and F. Wu, *ChemMedChem*, 2022, **17**, e202200003.
- 27 H. Wang, W. Su and M. Tan, *Innovation*, 2020, **1**, 100009.
- 28 P. Li, L. Sun, S. Xue, D. Qu, L. An, X. Wang and Z. Sun, *SmartMat*, 2022, **3**, 226–248.
- 29 M. Hu, X. Gu, Y. Hu, Y. Deng and C. Wang, *Macromol. Mater. Eng.*, 2016, **301**, 1352–1362.
- 30 D. Gao, P. Zhao, B. Lyu, Y. Li, Y. Hou and J. Ma, *Appl. Organomet. Chem.*, 2020, **34**, e5665.
- 31 Y. Wu, C. Li, H. C. van der Mei, H. J. Busscher and Y. Ren, *Antibiotics*, 2021, **10**, 623.
- 32 B. Sun, F. Wu, Q. Zhang, X. Chu, Z. Wang, X. Huang, J. Li, C. Yao, N. Zhou and J. Shen, *J. Colloid Interface Sci.*, 2021, **584**, 505–519.
- 33 D. I. Abu Rabe, M. M. Al Awak, F. Yang, P. A. Okonjo, X. Dong, L. R. Teisl, P. Wang, Y. Tang, N. Pan, Y. Sun and L. Yang, *Int. J. Nanomed.*, 2019, **14**, 2655–2665.
- 34 A. L. Lovering, S. S. Safadi and N. C. J. Strynadka, *Annu. Rev. Biochem.*, 2012, **81**, 451–478.
- 35 S. Ostovar Pour, L. Rocks, K. Faulds, D. Graham, V. Parchaňský, P. Bouř and E. W. Blanch, *Nat. Chem.*, 2015, **7**, 591–596.
- 36 N. Suzuki, Y. Wang, P. Elvati, Z. Qu, K. Kim, S. Jiang, E. Baumeister, J. Lee, B. Yeom, J. H. Bahng, J. Lee, A. Violi and N. A. Kotov, *ACS Nano*, 2016, **10**, 1744–1755.
- 37 Q. Xin, Q. Liu, L. Geng, Q. Fang and J. R. Gong, *Adv. Healthcare Mater.*, 2017, **6**, 1601011.
- 38 W. Bing, H. Sun, Z. Yan, J. Ren and X. Qu, *Small*, 2016, **12**, 4713–4718.
- 39 H. Jian, R. Wu, T. Lin, Y. Li, H. Lin, S. G. Harroun, J. Lai and C. Huang, *ACS Nano*, 2017, **11**, 6703–6716.
- 40 P. Li, Y. F. Poon, W. Li, H. Zhu, S. H. Yeap, Y. Cao, X. Qi, C. Zhou, M. Lamrani, R. W. Beuerman, E. Kang, Y. Mu, C. M. Li, M. W. Chang, S. S. Jan Leong and M. B. Chan-Park, *Nat. Mater.*, 2011, **10**, 149–156.
- 41 Y. Zhao, Z. Chen, Y. Chen, J. Xu, J. Li and X. Jiang, *J. Am. Chem. Soc.*, 2013, **135**, 12940–12943.



- 42 Y. Li, S. G. Harroun, Y. Su, C. Huang, B. Unnikrishnan, H. Lin, C. Lin and C. Huang, *Adv. Healthcare Mater.*, 2016, **5**, 2545–2554.
- 43 D. Ting, N. Dong, L. Fang, J. Lu, J. Bi, S. Xiao and H. Han, *ACS Appl. Nano Mater.*, 2018, **1**, 5451–5459.
- 44 N. Sattarahmady, M. Rezaie-Yazdi, G. H. Tondro and N. Akbari, *J. Photochem. Photobiol., B*, 2017, **166**, 323–332.
- 45 M. C. van Loosdrecht, J. Lyklema, W. Norde, G. Schraa and A. J. Zehnder, *Appl. Environ. Microb.*, 1987, **53**, 1893–1897.
- 46 C. Zhu, H. Li, H. Wang, B. Yao, H. Huang, Y. Liu and Z. Kang, *Small*, 2019, **15**, 1900007.
- 47 X. Hua, Y. Bao, H. Wang, Z. Chen and F. Wu, *Nanoscale*, 2017, **9**, 2150–2161.
- 48 Y. Song, H. Li, F. Lu, H. Wang, M. Zhang, J. Yang, J. Huang, H. Huang, Y. Liu and Z. Kang, *J. Mater. Chem. B*, 2017, **5**, 6008–6015.
- 49 F. Lu, Y. Song, H. Huang, Y. Liu, Y. Fu, J. Huang, H. Li, H. Qu and Z. Kang, *Carbon*, 2017, **120**, 95–102.
- 50 F. Lin, C. Li and Z. Chen, *Front. Microbiol.*, 2018, **9**, 2627.
- 51 J. Chen, W. Liu, Y. Li, X. Zou, W. Li, J. Liang, H. Zhang, Y. Liu, X. Zhang, C. Hu and B. Lei, *Chem. Eng. J.*, 2022, **428**, 131168.
- 52 H. Wang, Z. Song, J. Gu, S. Li, Y. Wu and H. Han, *ACS Biomater. Sci. Eng.*, 2019, **5**, 4739–4749.
- 53 J. Kang and D. Kang, *Chem. Eng. J.*, 2021, **420**, 129990.
- 54 N. A. Travlou, D. A. Giannakoudakis, M. Algarra, A. M. Labella, E. Rodríguez-Castellón and T. J. Bandoz, *Carbon*, 2018, **135**, 104–111.
- 55 L. Wang, Y. Li, Y. Wang, W. Kong, Q. Lu, X. Liu, D. Zhang and L. Qu, *ACS Appl. Mater. Interfaces*, 2019, **11**, 21822–21829.
- 56 Y. Sun, C. Shen, J. Wang and Y. Lu, *RSC Adv.*, 2015, **5**, 16368–16375.
- 57 J. Liu, X. Liu, H. Luo and Y. Gao, *RSC Adv.*, 2014, **4**, 7648–7654.
- 58 H. Wang, J. Xiao, Z. Yang, H. Tang, Z. Zhu, M. Zhao, Y. Liu, C. Zhang and H. Zhang, *J. Mater. Chem. A*, 2015, **3**, 11287–11293.
- 59 T. K. Mondal and S. K. Saha, *ACS Sustainable Chem. Eng.*, 2019, **7**, 19669–19678.
- 60 S. H. Jin, D. H. Kim, G. H. Jun, S. H. Hong and S. Jeon, *ACS Nano*, 2013, **7**, 1239–1245.
- 61 C. Zhu, Q. Yang, L. Liu, F. Lv, S. Li, G. Yang and S. Wang, *Adv. Mater.*, 2011, **23**, 4805–4810.
- 62 X. Li, S. M. Robinson, A. Gupta, K. Saha, Z. Jiang, D. F. Moyano, A. Sahar, M. A. Riley and V. M. Rotello, *ACS Nano*, 2014, **8**, 10682–10686.
- 63 H. Wang, X. Hua, F. Wu, B. Li, P. Liu, N. Gu, Z. Wang and Z. Chen, *ACS Appl. Mater. Interfaces*, 2015, **7**, 7082–7092.
- 64 J. Yang, X. Zhang, Y. Ma, G. Gao, X. Chen, H. Jia, Y. Li, Z. Chen and F. Wu, *ACS Appl. Mater. Interfaces*, 2016, **8**, 32170–32181.
- 65 Q. Dou, X. Fang, S. Jiang, P. L. Chee, T. Lee and X. J. Loh, *RSC Adv.*, 2015, **5**, 46817–46822.
- 66 B. Ju, H. Nie, X. Zhang, Q. Chen, X. Guo, Z. Xing, M. Li and S. X. Zhang, *ACS Appl. Nano Mater.*, 2018, **1**, 6131–6138.
- 67 J. Yang, G. Gao, X. Zhang, Y. Ma, X. Chen and F. Wu, *Carbon*, 2019, **146**, 827–839.
- 68 H. Ran, X. Cheng, Y. Bao, X. Hua, G. Gao, X. Zhang, Y. Jiang, Y. Zhu and F. Wu, *J. Mater. Chem. B*, 2019, **7**, 5104–5114.
- 69 C. Zhao, L. Wu, X. Wang, S. Weng, Z. Ruan, Q. Liu, L. Lin and X. Lin, *Carbon*, 2020, **163**, 70–84.
- 70 Z. Ye, G. Li, J. Lei, M. Liu, Y. Jin and B. Li, *ACS Appl. Bio Mater.*, 2020, **3**, 7095–7102.
- 71 M. Thakur, S. Pandey, A. Mewada, V. Patil, M. Khade, E. Goshi, M. Sharon and R. Cavalli, *J. Drug Delivery*, 2014, **2014**, 282193.
- 72 P. Hou, T. Yang, H. Liu, Y. F. Li and C. Z. Huang, *Nanoscale*, 2017, **9**, 17334–17341.
- 73 J. S. Sidhu, Mayank, T. Pandiyan, N. Kaur and N. Singh, *ChemistrySelect*, 2017, **2**, 9277–9283.
- 74 R. Jijie, A. Barras, J. Bouckaert, N. Dumitrascu, S. Szunerits and R. Boukherroub, *Colloids Surf., B*, 2018, **170**, 347–354.
- 75 J. Liu, S. Lu, Q. Tang, K. Zhang, W. Yu, H. Sun and B. Yang, *Nanoscale*, 2017, **9**, 7135–7142.
- 76 X. Dong, M. A. Awak, N. Tomlinson, Y. Tang, Y. Sun and L. Yang, *PLoS One*, 2017, **12**, e185324.
- 77 L. Zhao, M. Zhang, H. Wang and S. Devahastin, *Int. J. Food Microbiol.*, 2020, **326**, 108650.
- 78 H. Wang, M. Zhang, Y. Ma, B. Wang, M. Shao, H. Huang, Y. Liu and Z. Kang, *J. Mater. Chem. B*, 2020, **8**, 2666–2672.
- 79 H. Li, J. Huang, Y. Song, M. Zhang, H. Wang, F. Lu, H. Huang, Y. Liu, X. Dai, Z. Gu, Z. Yang, Z. Ruhong and Z. H. Kang, *ACS Appl. Mater. Interfaces*, 2018, **10**, 26936–26946.
- 80 Y. Song, F. Lu, H. Li, H. Wang, M. Zhang, Y. Liu and Z. Kang, *ACS Appl. Bio Mater.*, 2018, **1**, 1871–1879.
- 81 M. Debono and R. S. Gordee, *Annu. Rev. Microbiol.*, 1994, **48**, 471–497.
- 82 J. R. Scott and T. C. Barnett, *Annu. Rev. Microbiol.*, 2006, **60**, 397–423.
- 83 M. T. Cabeen and C. Jacobs-Wagner, *Nat. Rev. Microbiol.*, 2005, **3**, 601–610.
- 84 H. S. Hayden, S. Matamouros, K. R. Hager, M. J. Brittnacher, L. Rohmer, M. C. Radey, E. J. Weiss, K. B. Kim, M. A. Jacobs, E. H. Sims-Day, M. Yue, M. B. Zaidi, D. M. Schifferli, S. D. Manning, J. L. Walson, S. I. Miller, B. B. Finlay, W. D. Hardt and C. A. Aranda, *mBio*, 2016, **7**, e116–e154.
- 85 S. Santajit and N. Indrawattana, *Biomed Res. Int.*, 2016, **2016**, 2475067.
- 86 L. Huang, Y. Xuan, Y. Koide, T. Zhiyentayev, M. Tanaka and M. R. Hamblin, *Lasers Surg. Med.*, 2012, **44**, 490–499.
- 87 X. Jin, X. Sun, G. Chen, L. Ding, Y. Li, Z. Liu, Z. Wang, W. Pan, C. Hu and J. Wang, *Carbon*, 2015, **81**, 388–395.
- 88 B. S. B. Kasibabu, S. L. D. Souza, S. Jha and S. K. Kailasa, *J. Fluoresc.*, 2015, **25**, 803–810.
- 89 J. R. Bhamore, S. Jha, T. J. Park and S. K. Kailasa, *J. Photochem. Photobiol., B*, 2019, **191**, 150–155.
- 90 Y. Ma, Z. Ma, X. Huo, M. Gu, S. Ma, Y. Jing, Y. Wang, Y. Yue, Z. Feng and B. Tian, *J. Agric. Food Chem.*, 2020, **68**, 10223–10231.
- 91 Y. Chen, X. Sun, W. Pan, G. Yu and J. Wang, *Front. Chem.*, 2020, **7**, 911.



- 92 Y. Chen, X. Sun, X. Wang, W. Pan, G. Yu and J. Wang, *Spectrochim. Acta, Part A*, 2020, **233**, 118230.
- 93 M. A. Jhonsi, D. A. Ananth, G. Nambirajan, T. Sivasudha, R. Yamini, S. Bera and A. Kathiravan, *Spectrochim. Acta, Part A*, 2018, **196**, 295–302.
- 94 Z. Bagheri, H. Ehtesabi, Z. Hallaji, N. Aminoroaya, H. Taviana, E. Behroodi, M. Rahimifard, M. Abdollahi and H. Latifi, *Anal. Chim. Acta*, 2018, **1033**, 119–127.
- 95 S. Zhao, L. Huang, Y. Xie, B. Wang, F. Wang and M. Lan, *Chin. J. Chem. Eng.*, 2021, **37**, 97–104.
- 96 L. Chen and J. Liang, *Mater. Sci. Eng., C*, 2020, **112**, 110924.
- 97 P. Garg, S. Sangam, D. Kochhar, S. Pahari, C. Kar and M. Mukherjee, *Nano Today*, 2020, **35**, 101001.
- 98 P. Innocenzi and L. Stagi, *Chem. Sci.*, 2020, **11**, 6606–6622.
- 99 S. Kotta, H. M. Aldawsari, S. M. Badr-Eldin, N. A. Alhakamy, S. Md, A. B. Nair and P. K. Deb, *Front. Mol. Biosci.*, 2020, **7**, 616575.
- 100 S. Manivannan and K. Ponnuchamy, *Appl. Organomet. Chem.*, 2020, **34**, e5887.
- 101 A. H. Da Silva Júnior, D. L. Pier Macuvele, H. G. Riella, C. Soares and N. Padoin, *J. Mater. Res. Technol.*, 2021, **12**, 688–716.
- 102 G. Camlika, E. K. Akkolb, Z. Degima and I. T. Degima, *Iran. J. Pharm. Res.*, 2021, **20**, 9–20.
- 103 A. Barras, Q. Pagneux, F. Sane, Q. Wang, R. Boukherroub, D. Hober and S. Szunerits, *ACS Appl. Mater. Interfaces*, 2016, **8**, 9004–9013.
- 104 A. Boczechin, K. Séron, A. Barras, E. Giovanelli, S. Belouzard, Y. Chen, N. Metzler-Nolte, R. Boukherroub, J. Dubuisson and S. Szunerits, *ACS Appl. Mater. Interfaces*, 2019, **11**, 42964–42974.
- 105 Y. Y. Aung, A. N. Kristanti, S. Q. Khairunisa, N. Nasronudin and M. Z. Fahmi, *ACS Biomater. Sci. Eng.*, 2020, **6**, 4490–4501.
- 106 T. Du, J. Liang, N. Dong, L. Liu, L. Fang, S. Xiao and H. Han, *Carbon*, 2016, **110**, 278–285.
- 107 H. Liu, Y. Bai, Y. Zhou, C. Feng, L. Liu, L. Fang, J. Liang and S. Xiao, *RSC Adv.*, 2017, **7**, 28016–28023.
- 108 X. Dong, M. M. Moyer, F. Yang, Y. Sun and L. Yang, *Sci. Rep.*, 2017, **7**, 519.
- 109 X. Dong, R. Edmondson, F. Yang, Y. Tang, P. Wang, Y. Sun and L. Yang, *RSC Adv.*, 2020, **10**, 33944–33954.
- 110 S. Huang, J. Gu, J. Ye, B. Fang, S. Wan, C. Wang, U. Ashraf, Q. Li, X. Wang, L. Shao, Y. Song, X. Zheng, F. Cao and S. Cao, *J. Colloid Interface Sci.*, 2019, **542**, 198–206.
- 111 J. Cheng, Y. Xu, D. Zhou, K. Liu, N. Geng, J. Lu, Y. Liu and J. Liu, *Poultry Sci.*, 2019, **98**, 5315–5320.
- 112 C. Lin, L. Chang, H. Chu, H. Lin, P. Chang, R. Y. L. Wang, B. Unnikrishnan, J. Mao, S. Chen and C. Huang, *Small*, 2019, **15**, 1902641.
- 113 H. Huang, H. Lin, H. Huang, C. Huang, J. H. Lin and L. Chen, *Sci. Rep.*, 2020, **10**, 7343.
- 114 T. Tong, H. Hu, J. Zhou, S. Deng, X. Zhang, W. Tang, L. Fang, S. Xiao and J. Liang, *Small*, 2020, **16**, 1906206.

